Source:http://linkedlifedata.com/resource/pubmed/id/10741702
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2000-6-1
|
| pubmed:abstractText |
The purpose of this study was to retrospectively predict the chemotherapy response to paclitaxel in non-small cell lung cancer (NSCLC) using technetium-99m methoxyisobutylisonitrile (Tc-99m MIBI) chest single-photon-emission computed tomography (SPECT) to detect the expression of multidrug-resistance-mediated Mr 170,000 P-glycoprotein. Before chemotherapy with Paclitaxel (Taxol), 30 patients with stage IIIb or IV NSCLC were enrolled in this study. Early chest SPECT 10 min after i.v. injection of Tc-99m MIBI was performed to qualitatively interpret Tc-99m MIBI chest SPECT visually and quantitatively calculate early tumor:normal lung ratios (T:NL) for quick assessment of multidrug-resistant P-glycoprotein expression in NSCLC. On the basis of qualitatively visual interpretation of early Tc-99m MIBI chest SPECT, all of 15 (100%) cases with good response to chemotherapy with Taxol could be detected but 10 (67%) of 15 cases with poor response could not be detected. Early Tc-99m MIBI chest SPECT could correctly predict chemotherapy response in 25 (83%) of 30 of cases. The early T:NL were 3.30 +/- 0.82 for 15 patients with good response and 2.02 +/- 0.19 for 5 patients with poor response. The differences were significant (P < 0.05) by independent Student t tests. However, no significant differences were found for other prognostic factors (age, sex, tumor size, tumor location, stage, and cell type) between good-response and poor-response patients. Early Tc-99m MIBI chest SPECT has the potential to predict chemotherapy response to Paclitaxel.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1078-0432
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
6
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
820-4
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10741702-Adult,
pubmed-meshheading:10741702-Aged,
pubmed-meshheading:10741702-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:10741702-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:10741702-Female,
pubmed-meshheading:10741702-Humans,
pubmed-meshheading:10741702-Lung Neoplasms,
pubmed-meshheading:10741702-Male,
pubmed-meshheading:10741702-Middle Aged,
pubmed-meshheading:10741702-Neoplasm Staging,
pubmed-meshheading:10741702-P-Glycoprotein,
pubmed-meshheading:10741702-Paclitaxel,
pubmed-meshheading:10741702-Predictive Value of Tests,
pubmed-meshheading:10741702-Prognosis,
pubmed-meshheading:10741702-Retrospective Studies,
pubmed-meshheading:10741702-Technetium Tc 99m Sestamibi,
pubmed-meshheading:10741702-Tomography, Emission-Computed, Single-Photon,
pubmed-meshheading:10741702-Treatment Outcome
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single-photon-emission computed tomography.
|
| pubmed:affiliation |
Department of Nuclear Medicine, Taichung Veterans General Hospital, Taiwan. kao@vg40705.vghtc.gov.tw
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|